文献速递炎症性肠病

精准医学在炎症性肠病中的前景与挑战

Rise of precision medicine: can it deliver on its promise in IBD?
PubMed 文献 · Gut · 2025-12-05

本综述评估生物标志物指导的精准治疗在炎症性肠病(IBD)中的进展与局限,指出IBD缺乏可指导治疗选择的显性分子驱动因素,传统二元应答定义无法反映疗效的多维动态性,提出整合纵向应答动态和亚临床残余炎症连续监测的个体化综合疾病控制目标。

要点

  • IBD缺乏像肿瘤体细胞突变那样的可操作分子驱动层,预测性生物标志物仍难获得。
  • 传统单一时间点二元应答定义不能反映疗效的多维性和动态性。
  • 建议整合纵向患者报告结局与分子谱监测,实现从被动到主动的疾病管理。

核心结论

  • IBD的临床与分子异质性使真正个体化治疗策略的实施面临重大挑战。
  • 传统单一里程碑终点的二元应答定义无法反映治疗结局的多维动态本质。
  • 提出综合疾病控制等组合个体化终点,并整合纵向应答动态与亚临床残余炎症连续监测。

研究设计与样本

  • 综述,评估IBD中生物标志物指导精准治疗的当前进展与局限。

主要发现

  • IBD缺乏可检测的显性分子驱动因素来指导治疗选择。
  • 生物制剂和小分子药物拓宽了治疗格局,但预测治疗应答的生物标志物仍难以获得。
  • 纵向评估患者报告结局和分子谱可能作为长期结局的早期预测因素。

临床怎么用

  • 采用动态、数据驱动的治疗适应方法,可能将IBD管理从被动反应转为主动。
  • 纵向监测患者报告结局与分子谱,可指导早期治疗调整并揭示新治疗机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical and molecular heterogeneity of IBD-both between patients and within the same individual over time-continues to pose a significant challenge to the implementation of truly personalised treatment strategies. Unlike oncology, where somatic mutation patterns define an actionable information layer, IBD lacks detectable dominant molecular drivers that can guide therapeutic choices. Although the therapeutic landscape has broadened with the advent of numerous biologics and small molecule drugs, predictive (ex ante) biomarkers for treatment response remain elusive. In this review, we assess the current progress and limitations of biomarker-guided precision therapy in IBD. We argue that traditional binary response definitions at single landmark endpoints fail to reflect the multidimensional and dynamic nature of therapeutic outcomes. We hence propose combined, and thus individualised, endpoints such as comprehensive disease control as a more holistic and responsive therapy goal in IBD. We propose to integrate the individual longitudinal dynamics of treatment response, and also continuous, objective monitoring of subclinical residual inflammation, analogous to the concept of minimal residual disease in oncology. In this concept, longitudinal assessment of patient-reported outcomes and molecular profiling in response to therapy may serve as early predictors of long-term outcomes, guide early therapeutic adjustments and reveal mechanisms that open new therapeutic avenues, such as adjunct or combination treatments. Adopting this dynamic, data-driven approach to treatment adaptation could shift management of IBD from reactive to proactive and substantially improve long-term outcomes with the vision to fully control a life-long disease.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Schreiber S, Aden K, Tran F, et al. Rise of precision medicine: can it deliver on its promise in IBD? Gut. 2025. PMID: 41052915. doi:10.1136/gutjnl-2023-330000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。